Strongbridge Biopharma — Shareholder Meeting (April 2020)
9 slides from Strongbridge Biopharma's shareholder meeting presentation, Apr 20, 2020
Slide 1: Strongbridge Biopharma plc 2020 Annual General Meeting
Strongbridge Biopharma plc 2020 Annual General Meeting May 14, 2020
Slide 2: We Value Your Support at Our 2020 Annual General Meeting
We Value Your Support at Our 2020 Annual General Meeting • Our 2020 Annual General Meeting is on May 14, 2020. Our Board of Directors recommends that you vote "FOR" each of the nominees in Proposal 1 and "FOR" each of the other proposals. This document contains information on Proposals 3, 4 and 5, w
Slide 3: Background on Share Issuance Proposals (Proposals 3 and 4)
Background on Share Issuance Proposals (Proposals 3 and 4) – We are incorporated in Ireland – but we are listed exclusively on the Nasdaq exchange and we file all reports with the SEC as a U.S. domestic issuer Because we are incorporated in Ireland and listed in the U.S. on the Nasdaq - we must comp
Slide 4: Comparison of Irish Law and Nasdaq Rules on Share Issuance Authority and Pre-emption
Comparison Of Irish Law and Nasdaq Rules on Share Issuance Authority and Shareholder Pre-emption Proposals 3 and 4 renew these important exemptions for five years, giving our directors the authority to issue shares without first obtaining shareholder approval and to do so without first offering pre-
Slide 5: Why You Should Vote "For" Proposals 3 and 4
Why You Should Vote “For” Proposals 3 and 4 as Keveyis, Recorlev and veldoreotide. We rely on having the flexibility continued development and commercialization of these products and of our business and growth strategy. The ability to quickly raise and 5 Reason Explanation Fundamental to the way we
Slide 6: Why You Should Vote "For" Proposals 3 and 4 (continued)
Why You Should Vote “For” Proposals 3 and 4 greater flexibility than us to raise capital and pursue acquisitions and ability to continue to develop our product candidates and to execute on would have no limits on future share issuances. company under SEC rules 6 Reason Explanation Keep us on an equa
Slide 7: We Have Used Equity Offerings in the Past to Advance Our Growth Strategy
We Have Used Equity Offerings in the Past to Advance Our Growth Strategy Our strategy has been to evolve the Company to become a biopharma company focused on the development and commercialization of therapies for rare diseases, which we have effected in part through acquisitions or similar transacti
Slide 8: Why Proposal 5 is on the Agenda and Why You Should Vote "FOR"
Why Proposal 5 is on the Agenda and Why You Should Vote "FOR" Proposal 5 Proposal 4 - to renew our directors' authority to issue shares for cash without first offering shares to existing shareholders is a special resolution under Irish law requiring an affirmative vote of 75% of the votes cast on th
Slide 9: Strongbridge Biopharma plc
Strongbridge Biopharma plc 9
Strongbridge Biopharma — Shareholder Meeting (April 2020) on 6ix